anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: This study estimated the magnitude and duration of risk of cardiovascular events and mortality following acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and whether risks varied by number and severity of exacerbation in a commercially insured population in the United States.
METHODS: This was a retrospective cohort study of newly diagnosed COPD patients ≥40 years old in the Healthcare Integrated Research Database from 2012 to 2019. Patients experiencing exacerbations comprised the "exacerbation cohort". Moderate exacerbations were outpatient visits with contemporaneous antibiotic or glucocorticoid administration; severe exacerbations were emergency department visits or hospitalizations for AECOPD. Follow-up started on the exacerbation date. Distribution of time between diagnosis and first exacerbation was used to assign index dates to the "unexposed" cohort. Cox proportional hazards models estimated risks of a cardiovascular event or death following an exacerbation adjusted for medical and prescription history and stratified by follow-up time, type of cardiovascular event, exacerbation severity, and rank of exacerbation (first, second, or third).
RESULTS: Among 435,925 patients, 170,236 experienced ≥1 exacerbation. Risk of death was increased for 2 years following an exacerbation and was highest during the first 30 days (any exacerbation hazard ratio (HR)=1.79, 95% CI=1.58-2.04; moderate HR=1.22, 95% CI=1.04-1.43; severe HR=5.09, 95% CI=4.30-6.03). Risks of cardiovascular events were increased for 1 year following an AECOPD and highest in the first 30-days (any exacerbation HR=1.34, 95% CI=1.23-1.46; moderate HR=1.23 (95% CI 1.12-1.35); severe HR=1.93 (95% CI=1.67-2.22)). Each subsequent AECOPD was associated with incrementally higher rates of both death and cardiovascular events.
CONCLUSION: Risk of death and cardiovascular events was greatest in the first 30 days and rose with subsequent exacerbations. Risks were elevated for 1-2 years following moderate and severe exacerbations, highlighting a sustained increased cardiopulmonary risk associated with exacerbations.
The invention belongs to the technical field of medicines, and provides application of dexmedetomidine in preparing a medicine for treating acute and chronic itching. Wherein the medicine for treating acute and chronic itching at least contains dexmedetomidine which is taken as the only active ingredient. Use of dexmedetomidine in the manufacture of a medicament for the treatment of histamine-dependent acute itch induced by C48/80. Use of dexmedetomidine in the preparation of a medicament for the treatment of CQ-induced histamine-independent acute itch. Application of dexmedetomidine in preparing medicine for treating DCP-induced chronic itching. According to the invention, the inhibition effect of dexmedetomidine on itch is researched through an acute itch model induced by C48/80 and CQ and a chronic itch model induced by DCP, and experimental results show that the intrathecal injection of dexmedetomidine is dose-dependent and can significantly inhibit scratching reactions caused by acute and chronic itch of mice, so that the dexmedetomidine is proved to have the effect of relieving the acute and chronic itch.
PURPOSE: To address the unique challenges presented by hypospadias repair in toilet-trained boys, we propose a modification to the standard stenting technique: implementation of a mid-urethral stent (MUS) extending beyond the urethroplasty, terminating distally to the sphincter mechanism. This modification upholds continence while facilitating normal voiding.
METHODS: Toilet-trained boys undergoing hypospadias repair from 2009 to 2020 were retrospectively assessed. Patients were allocated into one of two groups: "Continent" drainage (a short stent was placed across the urethroplasty) or "incontinent" drainage (a standard stent or a Foley catheter was placed). Stent- related complications (dislodgement and obstruction) and surgical outcomes were compared.
RESULTS: 545 children underwent hypospadias repair with 96 (17.6%) of them toilet-trained. The "continent" and "incontinent" groups consisted of 44 and 52 patients. No differences were found regarding age, severity of hypospadias, number of corrective procedures, operative time or surgical technique. Rates of stent-related complications did not differ. No significant difference was found regarding complications requiring additional surgery, including meatal stenosis and dehiscence. Post-operative fistula occurred in one patient in the continent group and in seven patients in the incontinent group.
CONCLUSION: Use of a continence-preserving MUS is a safe alternative in toilet-trained patients undergoing hypospadias repair without increasing risk of complications.
The research team will test these hypotheses via a randomized, double-blind, placebo-controlled pilot study of citicoline in individuals with AD. Participants will be recruited from the Alzheimer's Disease Research Center (ADRC) and from the community in the surrounding Atlanta area. This will be a 3-month randomized, double-blind, placebo-controlled trial comparing citicoline and placebo in a well-characterized cohort of 20 individuals with AD. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). For neuropsychological and cognition will be measured measures, the research team will employ the Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA).

Those participating in the ADRC parent study or recruited from the community and diagnosed with AD in their medical record and aged 18 and over are eligible to participate. Eligible participants will be enrolled in a two-treatment trial comparing the effects of citicoline (1000 mg once per day with or without food) to a placebo. There will be a baseline (T0) visit and a follow-up 3 months later (T1) as a separate visit.
Client motivation is related to therapeutic change (Ryan, Lynch, Vansteenkiste, \& Deci) and low motivation is a pervasive issue for clients with BPD (e.g., Skodal et al., 1983). DBT (Linehan, 1993) is an effective treatment for BPD and was developed in part to address client motivation. Within DBT there are commitment strategies that are used to help clients establish clear goals and increase motivation to work on them. These strategies were designed to help people commit to eliminating self-harm as well as other behaviours. People are more motivated to work effectively towards goals for which they are autonomously motivated (Deci \& Ryan, 2000). Despite their importance in DBT, commitment strategies have never been studied. This study will examine whether commitment strategies are associated with an increase in autonomous motivation and a decrease in self harm behaviour.

This research will address two primary questions: 1) Are commitment strategies associated with an increase in autonomous motivation to decrease self-harm behaviour?; and 2) Does autonomous motivation mediate a relationship between commitment strategies and change in self-harm behaviour? The investigators will also address a secondary question related to predictors of autonomous motivation. Our hypotheses are as follows: 1) The group receiving psychoeducation enhanced with commitment strategies will have higher levels of autonomous motivation compared to the psychoeducation control group; and 2) autonomous motivation will mediate the relationship between commitment strategies and decreases in self harm behaviour. Additionally, autonomy support, low therapist judgment, and goal concordance between client and therapist will independently contribute to predicting client autonomous motivation.

Research in this area is needed in light of the challenges presented by the low motivation that often characterizes individuals with borderline traits who engage in self-harm behaviour. No studies to date have examined DBT's commitment strategies, thus, the effect of these treatment strategies is unknown and needs to be established. Additionally, identifying specific variables that are associated with motivation to eliminate self-harm will help inform the refinement treatment strategies. Finally, few studies have examined the role of autonomous motivation and treatment outcome.
Institutional Review Board- Park Nicollet Institute approval was granted 3/2011 for 15 patients to be enrolled in pilot study of use of a bioabsorbable ventilation ear (PE) tube. IRB stated compliance with FDA as defined in 21 CFR, Part 56 and with regulations of DHHS. Federal assurance number FWA00000914. Prior to commencing this study, IRB approval was obtained and each participating clinician completed the NIH training for "Protecting Human Research Participants".

14 patients (15 ears) were enrolled in this study and were examined by 2 independent examiners at approximately 3, 6 and 12 week follow-ups. Lumen patency and time to complete resorption were documented by each examiner. There were no adverse reactions. This pilot study suggests that there is utility for a bioabsorbable ear tube made from gelatin material, as the device was found to break down over the expected time frame and remained functional long enough to have clinical utility.
The International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee aims to improve the use of drugs in older adults and develop new therapeutic approaches for the syndromes and diseases of old age through advocacy, education, and research. In the present paper, we propose strategies relevant to drug development and evaluation, spanning preclinical and the full range of clinical studies. Drugs for older adults need to consider not only age, but also other characteristics common in geriatric patients, such as multimorbidity, polypharmacy, falls, cognitive impairment, and frailty. The IUPHAR Geriatric Committee's position statement on 'Measurement of Frailty in Drug Development and Evaluation' is included, highlighting 12 key principles that cover the spectrum of translational research. We propose that where older adults are likely to be major users of a drug, that frailty is measured at baseline and as an outcome. Preclinical models that replicate the age, frailty, duration of exposure, comorbidities, and co-medications of the proposed patients may improve translation. We highlight the potential application of recent technologies, such as physiologically based pharmacokinetic-pharmacodynamic modeling informed by frailty biology, and Artificial Intelligence, to inform personalized medicine for older patients. Considerations for the rapidly aging populations in low- and middle-income countries related to health-care and clinical trials are outlined. Involving older adults, their caregivers and health-care providers in all phases of research should improve drug development, evaluation, and outcomes for older adults internationally.
BACKGROUND: Phytosphingosine and its derivative are known for their skin-protective properties. While mYG-II-6, a phytosphingosine derivative, has shown anti-inflammatory and antipsoriatic effects, its potential antipruritic qualities have yet to be explored. This study aimed to investigate mYG-II-6's antipruritic properties.
METHODS: The calcium imaging technique was employed to investigate the activity of ion channels and receptors. Mast cell degranulation was confirmed through the β-hexosaminidase assay. Additionally, in silico molecular docking and an in vivo mouse scratching behavior test were utilized.
RESULTS: Using HEK293T cells transfected with H1R and TRPV1, we examined the impact of mYG-II-6 on histamine-induced intracellular calcium rise, a key signal in itch-mediating sensory neurons. Pretreatment with mYG-II-6 significantly reduced histamine-induced calcium levels and inhibited TRPV1 activity, suggesting its role in blocking the calcium influx channel. Additionally, mYG-II-6 suppressed histamine-induced calcium increase in primary cultures of mouse dorsal root ganglia, indicating its potential antipruritic effect mediated by histamine. Interestingly, mYG-II-6 exhibited inhibitory effects on human MRGPRX2, a G protein-coupled receptor involved in IgE-independent mast cell degranulation. However, it did not inhibit mouse MrgprB2, the ortholog of human MRGPRX2. Molecular docking analysis revealed that mYG-II-6 selectively interacts with the binding pocket of MRGPRX2. Importantly, mYG-II-6 suppressed histamine-induced scratching behaviors in mice.
CONCLUSIONS: Our findings show that mYG-II-6 can alleviate histamine-induced itch sensation through dual mechanisms. This underscores its potential as a versatile treatment for various pruritic conditions.
Healthy dieters will undergo a single-visit neuroimaging study where they will first complete demographic and self-report measures followed by a self-control decision task in an fMRI scanner. Prior to scanning, participants will be assigned to the social stress group and complete the corresponding stress task. For the social stress group, this task is the Trier Social Stress Test (TSST), a psychosocial stressor that requires participants perform a short speech and solve math problems in front of 2 evaluative judges. After the scan, participants will wait for 1 hour in an adjacent study room where they will play out one trial of the decision-making task completed in the scanner.
Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
FIELD: medicine, vaccine production. SUBSTANCE: patients were given vaccinotherapy using mixed vaccine consisting of antigens of Klebsiella pneumonia, Proteus, Staphylococcus and Escherichia coli. Vaccine can be used by subcutaneously route and also by combined intranasal-subcutaneous and intranasal-oral routes. Proposed vaccinotherapy using this mixed vaccine provides decrease of frequency and severity of relapses course, decreased level of drug consumption (antibiotics, sympathomimetics, hormones). Mixed vaccine provides good effect in 70-80% patient suffering with chronic bronchitis, infection-dependent form of bronchial asthma. EFFECT: making mixed vaccine, enhanced effectiveness and prophylaxis in chronic inflammatory diseases.
For the manufacture of an ophthalmic lens, the ophthalmic lens includes a gel matrix, at least one first polyelectrolyte coating layer, at least one second polyelectrolyte coating layer, and drugs. The first polyelectrolyte coating layer is formed on the gel matrix. The second polyelectrolyte coating layer is formed on the first polyelectrolyte coating layer. The drugs are in place between the first polyelectrolyte coating layer and the second polyelectrolyte coating layer. The first polyelectrolyte coating layer and the second polyelectrolyte coating layer interact electrostatically. When intraocular pressure (TOP) rises, the electrostatic interaction between the first polyelectrolyte coating layer and the second polyelectrolyte coating layer is broken and the drugs are released.
PCT No. PCT/EP93/00911 Sec. 371 Date Dec. 1, 1994 Sec. 102(e) Date Dec. 1, 1994 PCT Filed Apr. 15, 1993 PCT Pub. No. WO93/21202 PCT Pub. Date Oct. 26, 1993The invention relates to synthetic phosphorothioated or partially phosphorothioated oligodeoxynucleotides capable of selectively modulating hemopoietic bone marrow cells development. More particularly, the invention relates to synthetic antisense oligodeoxynucleotides directed against a region spanning the AUG initiation condon in human ACHE or 2HS genes, having phosphorothioate bonds linking between the nucleotide bases; synthetic antisense oligodeoxynucleotides directed against a region spanning the AUG initiation condon in human ACHE gene, 2HS gene or BCHE gene or against a 5'-region in the human CHED (cdc2 homolog) gene, having phosphorothioate bonds linking between the four 3'-terminus nucleotide bases. The invention also relates to pharmaceutical compositions comprising as active ingredient at least one synthetic phosphorothioated or partially phosphorothioated antisense oligodeoxynucleotides according to the invention in physiologically acceptable carrier in diluent. The antisense oligodeoxynucleotides of the invention and the pharmaceutical compositions containing them are suitable for inhibiting abnormal hemopoietic cells proliferation, inhibiting abnormal platelet proliferation, increasing stem cell fraction in bone marrow cell cultures, enhancing macrophage production and increasing stem cells counts, reducing immune response of organs to be transplanted, suppressing immune response of a recipient of an allotransplanted organ, and arresting growth of malignant tumors.
Eligible patients will be referred for radiation oncology consultation by the operating surgeon. Patients will be presented with all radiation options and if they choose IORT, they will be offered enrollment onto the registry trial and consented accordingly. The registry will collect treatment data from the operation, radiation and pathology notes post IORT for each patient enrolled. Sources of research material, i.e. resected breast tissue and lymph nodes, will be obtained as part of routine clinical care. No additional tissue will be collected from patients due to enrollment on this registry trial. No additional studies will be performed outside of the routine standard of care.

Post treatment, the registry will collect data based on the standard of care follow up schedule. Follow-up visits will be scheduled 2-3 weeks post-operatively, as per standard of care, to review the final pathology and for the initial toxicity assessment. Patients found to have positive margins and/or lymph node involvement may require further surgery and/or additional external beam radiation. Additional follow-up visits with radiation oncology will be scheduled at 6 months and 1, 2, 3, 4, and 5 years following IORT. Toxicity will be scored using CTCAE v4.03. Local control will be evaluated using clinical exam and semi-annual to annual mammograms. All such information will be tracked and recorded into the registry database.
PROBLEM TO BE SOLVED: To provide a new composition with an anticandidal activity which achieves a more powerful effect on candidiasis of a skin and a mucous membrane, including elderly person's mycotic stomatitis and female's vaginal candidiasis, both of which particularly are infectious diseases with a lot of numbers of patients and tend to have a relapse, than conventional products, which can be used for a long period of time without worrying about a risk of any side effect and/or of any resistant bacteria, and which is easily obtainable and usable for a patient.SOLUTION: Although both of shogaol which is an ingredient of a flavor plant, and capric acid which is an ingredient of a dry crude drug and is also a food additive, independently exhibit an anticandidal activity, a synergism is exerted when both are used together, and as a result their effect can be improved remarkably. Moreover, it is easy for both shogaol and capric acid to obtain high purity products, and both are approved of using for food. Therefore, both shogaol and capric acid can be applied to a wide range of products, ranging from medicine to food, and when they are put to a practical use, a patient can easily obtain and use a certain product. Although mycotic stomatitis and vaginal candidiasis tend to have a relapse, when the composition includes a plant constituent or a food additive, a risk caused by an application of an antifungal agent is not to be worried about, and the patient can use the composition at ease. Moreover, when compared at an equivalent level of effectiveness, the product, making full use of the synergism, can significantly lower an added amount of each ingredient. In a food industry in which flavor is regarded as important, a flexibility of formulation increases, and expansion of application products is achieved.
Specific liposomes for the elimination of HIV and cells infected by it. Liposomes with CD4 molecules adsorbed on their surface, which contain a protease (e.g. trypsin) or else an RNAse (e.g. ribonuclease T) and which are specific for the elimination of HIV and of the cells infected by it. When a liposome bearing protease coalesces with an HIV particle, the protease destroys its nucleocapsid; if the liposome contains ribonuclease, the latter destroys the viral RNA. The cells infected (carrying pg120) are destroyed when they coalesce with liposomes with encapsulated protease.
<P>PROBLEM TO BE SOLVED: To provide a sheet-like cosmetic material not only having appearance providing an impression of good wipeability, but also having good wipeability in use, good touch feeling and good sense of use hardly causing twisting.  <P>SOLUTION: In the sheet-like cosmetic material, a web layer A comprising a viscose rayon using cotton linters as a starting material as a constituent fiber, and a web B including a fusing fiber in a constituent fiber are laminated, and the constituent fibers of the web A and the web B are mutually interlaced to provide a spunlace nonwoven fabric. The spunlace nonwoven fabric and a heat-fusible sheet including the fusing fiber are laminated in order of web A/web B/heat-fusible sheet/web B/web A. The sheet material is constituted by integrating the laminate by forming a shape in which an uneven pattern is formed by hot embossing at least on one surface of the laminate. Also provided is a sheet material which is prepared by the impregnation of a liquid material to the above sheet like material.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Participants will receive either PVd or DPd as a standard therapy. In PVd treatment, participants will receive oral pomalidomide 4 mg on Days 1 to 14 in each cycle; bortezomib 1.3 mg/meter square (m\^2) SC on Days 1, 4, 8 and 11 (Cycles 1 to 8) and on Days 1 and 8 (Cycle 9 onwards) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8) and Days 1, 2, 8 and 9 (Cycle 9 onwards). Each cycle will consist of 21 days. In DPd treatment, participants will receive daratumumab SC 1800 mg weekly on Days 1, 8, 15, and 22 (Cycles 1 and 2), every 2 weeks on Days 1 and 15 (Cycles 3 to 6) and every 4 weeks on Day 1 (Cycle 7 onwards); oral pomalidomide 4 mg on Days 1 to 21 (Cycle 1 onwards); dexamethasone 40 mg oral or IV weekly on Days 1, 8, 15, and 22 (Cycle 1 onwards). Each cycle will consist of 28 days. Participants will continue to receive PVd or DPd until confirmed PD, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs earlier.
PURPOSE:To obtain the titled composition, storable at room temperature for a long term, and orally or parenterally administrable, by incorporating a fermented a fermented milk with honey and a specific stabilizer, homogenizing the resultant mixture, and instantaneously pasteurizing the resultant homogenized mixture at an ultrahigh temperature. CONSTITUTION:A nutrimental composition prepared by incorporating 100pts.wt. fermented milk with 18-22pts.wt. honey and further ultrahigh methoxypectin (UHM pectin) and propylene glycol ester (PGA) of alginic acid as a stabilizer without causing the separation and settling of the contents even on the instantaneous pasteurization at an ultrahigh temperature. Preferably, the above-mentioned UHM pectin is added in an amount of 0.1-1.0%, and the PGA is added in an amount of 0.05-0.5%. The above-mentioned fermented milk is obtained by adding skimmilk powder, water and if necessary a fat or oil to a cow's milk, and inoculating the prepared milk with a lactic acid bacterial starter, and cultivating the bacterial starter at 3.5-4.5pH.